TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $11.79 Consensus Target Price from Brokerages

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have received an average rating of “Buy” from the nine brokerages that are covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $11.79.

A number of equities analysts have recently weighed in on the company. Oppenheimer initiated coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price on the stock. Cantor Fitzgerald assumed coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective for the company. Northland Securities assumed coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 target price for the company. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Finally, Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th.

Insiders Place Their Bets

In other news, major shareholder Equity Ab Frankenius acquired 62,972 shares of the business’s stock in a transaction dated Tuesday, December 17th. The stock was bought at an average cost of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the transaction, the insider now owns 6,230,748 shares of the company’s stock, valued at $24,736,069.56. The trade was a 1.02 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders acquired 70,012 shares of company stock worth $281,235 over the last quarter. 32.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Duquesne Family Office LLC boosted its position in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the period. Highbridge Capital Management LLC purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at about $1,184,000. Geode Capital Management LLC grew its position in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares during the last quarter. MSD Partners L.P. bought a new stake in TriSalus Life Sciences in the third quarter valued at approximately $184,000. Finally, Vestcor Inc purchased a new stake in shares of TriSalus Life Sciences during the third quarter valued at approximately $108,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Performance

Shares of TLSI stock opened at $4.90 on Thursday. The company has a market capitalization of $149.42 million, a price-to-earnings ratio of -1.97 and a beta of 0.51. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $10.42. The company has a 50-day simple moving average of $4.38 and a two-hundred day simple moving average of $4.79.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.